SCHEMBL4040938

SCHEMBL4040938

O=C(NC(Cc1cccs1)C(=O)N1CCC2C1C(=O)CN2S(=O)(=O)Cc1ccccn1)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSK P43235 7/20 0.40
MAPK14 Q16539 1/20 0.39
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
SLC5A7 Q9GZV3 1/20 0.36
CTSS P25774 3/20 0.35
CTSV O60911 2/20 0.35
CTSL P07711 2/20 0.35
USP30 Q70CQ3 1/20 0.34
MMP13 P45452 1/20 0.34
ADAM17 P78536 2/20 0.34
CTSB P07858 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
GPR132 Q9UNW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4046634 0.90 CTSK (0.51) CTSKLMNAALDH1A1PKMCTSS
SCHEMBL4040459 0.90 CTSK (0.39) CTSKCTSSCTSVCTSLUSP30
SCHEMBL4041519 0.90 CTSK (0.42) CTSKCTSSCTSVCTSLCTSB
SCHEMBL4041707 0.88 CTSS (0.43) CTSKMAPK14LMNAALDH1A1PKM
SCHEMBL4038859 0.88 CTSK (0.53) CTSKMAPK14LMNAALDH1A1PKM
SCHEMBL4040930 0.88 ACE (0.40) CTSKCTSSCTSVCTSLMMP13
SCHEMBL4042823 0.88 CTSK (0.40) CTSKMAPK14CTSSCTSVCTSL
SCHEMBL4045232 0.88 CTSK (0.44) CTSKMAPK14LMNAALDH1A1PKM
SCHEMBL4220750 0.85 CTSK (0.40) CTSKCTSSCTSVCTSLUSP30
SCHEMBL4039009 0.85 CTSK (0.41) CTSKALDH1A1CTSSCTSVCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP claimed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO claimed
EP-1678157-A4 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF REDDY US THERAPEUTICS INC (US) 2009-03-18 EP disclosed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
EP-1140908-B1 TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY ABBOTT GMBH & CO KG (DE) 2009-03-04 EP disclosed
EP-1678157-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF Reddy US Therapeutics, Inc. (US) 2006-07-12 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed
WO-2005042712-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF REDDY US THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885MAPK14 3342/4885LMNA 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.